Folger Nolan Fleming Douglas Capital Management Inc. decreased its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 80.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,008 shares of the medical research company’s stock after selling 4,218 shares during the quarter. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Amgen were worth $101,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Oregon Public Employees Retirement Fund grew its holdings in Amgen by 20,103.6% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 31,424,215 shares of the medical research company’s stock worth $161,000 after buying an additional 31,268,677 shares in the last quarter. Capital International Investors grew its holdings in Amgen by 301.4% during the third quarter. Capital International Investors now owns 11,093,182 shares of the medical research company’s stock worth $2,299,506,000 after buying an additional 8,329,861 shares in the last quarter. Capital World Investors bought a new stake in Amgen during the third quarter worth $952,900,000. FMR LLC grew its holdings in Amgen by 4.4% during the third quarter. FMR LLC now owns 35,823,268 shares of the medical research company’s stock worth $7,425,805,000 after buying an additional 1,505,266 shares in the last quarter. Finally, BlackRock Inc. boosted its position in Amgen by 2.0% in the fourth quarter. BlackRock Inc. now owns 46,127,396 shares of the medical research company’s stock worth $8,979,621,000 after purchasing an additional 906,568 shares during the last quarter. Hedge funds and other institutional investors own 79.18% of the company’s stock.
A number of research analysts have recently commented on the company. Mizuho set a $208.00 price target on Amgen and gave the company a “buy” rating in a research report on Friday, April 12th. Zacks Investment Research cut Amgen from a “buy” rating to a “hold” rating in a research report on Wednesday, January 23rd. Royal Bank of Canada reaffirmed a “neutral” rating and set a price target on shares of Amgen in a research report on Monday, January 14th. Cowen reaffirmed a “buy” rating and set a $234.00 price target on shares of Amgen in a research report on Tuesday, February 26th. Finally, BidaskClub cut Amgen from a “buy” rating to a “hold” rating in a report on Wednesday, February 20th. Eleven investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $209.11.
Shares of Amgen stock traded down $5.00 during trading on Friday, hitting $177.47. 8,266,592 shares of the stock traded hands, compared to its average volume of 2,669,918. The company has a current ratio of 2.79, a quick ratio of 2.57 and a debt-to-equity ratio of 2.36. The firm has a market capitalization of $109.31 billion, a PE ratio of 12.32, a price-to-earnings-growth ratio of 2.17 and a beta of 1.21. Amgen, Inc. has a 52 week low of $165.22 and a 52 week high of $210.19.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, January 29th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.26 by $0.16. The firm had revenue of $6.23 billion for the quarter, compared to analyst estimates of $5.88 billion. Amgen had a return on equity of 66.74% and a net margin of 35.35%. During the same period in the prior year, the company earned $2.89 EPS. As a group, analysts predict that Amgen, Inc. will post 13.96 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a dividend of $1.45 per share. This represents a $5.80 annualized dividend and a yield of 3.27%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio is presently 40.28%.
WARNING: This report was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/amgen-inc-amgn-shares-sold-by-folger-nolan-fleming-douglas-capital-management-inc.html.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Recommended Story: How to calculate the annual rate of depreciation
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.